Hematology, Transfusion and Cell Therapy最新文献

{"title":"The challenge of timely diagnosis and management of acute leukemias and associated infections in Latin America","authors":"","doi":"10.1016/j.htct.2024.08.001","DOIUrl":"10.1016/j.htct.2024.08.001","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924002906/pdfft?md5=e95d49d727337bd3bd46e66221171355&pid=1-s2.0-S2531137924002906-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and its absolute commitment to ethics and absence of conflicts of interest","authors":"Carmino Antonio de Souza , Eduardo Magalhães Rego , Glaciano Nogueira Ribeiro , Silvia Maria Meira Magalhães , Celso Arrais Rodrigues da Silva , Leny Nascimento da Motta Passos , Dimas Tadeu Covas , Renato Sampaio Tavares , Vania T.de Moraes Hungria , Edvan de Queiroz Crusoé , José Francisco Comenalli Marques Jr , Carlos Sérgio Chiattone , Dante Langhi Junior , Jorge Vaz Pinto Neto , Violete Petitto Laforga , Angelo Maiolino","doi":"10.1016/j.htct.2024.05.003","DOIUrl":"10.1016/j.htct.2024.05.003","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924002608/pdfft?md5=98db4956188c88b38a570b73b54387c8&pid=1-s2.0-S2531137924002608-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy","authors":"","doi":"10.1016/j.htct.2024.05.002","DOIUrl":"10.1016/j.htct.2024.05.002","url":null,"abstract":"<div><p>Improvements in clinical assessment have occurred since the last published recommendations on the diagnosis and treatment of acute promyelocytic leukemia in 2013. Here, a committee of specialists of the <em>Brazilian Association of Hematology, Hemotherapy and Cellular Therapy</em> presents a comprehensive review on the current knowledge, focusing on the advances in diagnosis, risk assessment, and frontline and salvage therapy. The concept of urgent diagnosis is explored as well as the management of critical situations such as coagulopathy and differentiation syndrome. Recent adjustments in risk stratification based on white blood cell counts only are presented together with the incorporation of chemo-free regimens for non-high-risk patients. Special conditions such as acute promyelocytic leukemia in children, the elderly and pregnant women are discussed. Finally, acute promyelocytic leukemia is presented as a highly curable disease because of the real possibility of targeted therapy towards differentiation, and, paradoxically, as a serious and urgent condition that deserves prompt recognition and management to avoid early mortality.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924002530/pdfft?md5=469a1e38f9b9d2a446b0e200c5796e2d&pid=1-s2.0-S2531137924002530-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141134276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MEDIASTINAL GRAY ZONE LYMPHOMA; SHADES OF GRAY","authors":"Meral Ulukoylu Menguc ,&nbsp;Fatma Arıkan ,&nbsp;Tayfur Toptas","doi":"10.1016/j.htct.2024.04.031","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.031","url":null,"abstract":"<div><h3>Objective</h3><p>Mediastinal gray zone lymphoma (MGZL) is a rare B cell lymphoma originated from the thymic niche. An incostistency between morphological and immunohistochemical findings is the hallmark of the disease . Both 2022 WHO classification and International Consensus Classification renamed the disease as Mediastinal Gray Zone Lymphoma which excluded non-mediastinal forms. Due to rarity and clinical presentation of mediastinal bulky disease prospective trials for the management of MGZL is limited.</p><p>Case report: Twenty-nine years old female patient admitted to hospital with dyspnea and night sweats. Basal scans showed an anterior mediastinal mass lesion of 5 × 5 × 6 cm diameter. Tru-cut biopsy of the lesion showed MGZL, cHL -like subtype with immunohistochemically CD 30, CD15, PAX-5 positivity and strong CD20 positive giant cell containing atypical lymphoproliferative mass in a sclerotic background . Background consisted of numerous mature lymphocytes, rare eosinophils, histiocytes and plasma ce</p></div><div><h3>Methodology</h3><p>PET-CT showed anterior mediastinal mass of 8,7 X 6,2 cm standing just behind pericardium with a SUVmax of 28,3 . Along with mediastinal mass right prevascular,preparacardiac and anterior diaphragmatic lympadenopaties of maximum length of 2,5 cm and with a SUVmax ranging between 7,04 and 24,7 were detected. Basal tests showed iron deficiency anemia of hemoglobin 9,8 g/dl and erythrocyte sedimentation rate of 29 mm/hour. LDH was 645 IU/l. Pretherapy echocardiograpy showed pericardial effusion</p></div><div><h3>Results</h3><p>Background consisted of numerous mature lymphocytes, rare eosinophils, histiocytes and plasma cells . PET-CT showed anterior mediastinal mass of 8,7 X 6,2 cm standing just behind pericardium with a SUVmax of 28,3 . Along with mediastinal mass right prevascular,preparacardiac and anterior diaphragmatic lympadenopaties of maximum length of 2,5 cm and with a SUVmax ranging between 7,04 and 24,7 were detected. Basal tests showed iron deficiency anemia of hemoglobin 9,8 g/dl .</p></div><div><h3>Conclusion</h3><p>Targeted therapies especially PD-1 blockage and anti-CD30 therapies are increasingly filling the gap for the management of GZL s as well as cHL and PMBCL. Brentuximab vedotin is a promising agent for the management of GZLs both in the first line and in the relapsed/ refractory setting.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001135/pdfft?md5=0de6476f0a2b8aad50379ba7c9d68294&pid=1-s2.0-S2531137924001135-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACUTE MYELOID LEUKEMIA DIAGNOSED WITH CUTANEOUS INVOLVEMENT; A RARE CASE","authors":"HATICE AYAG ,&nbsp;Müzeyyen Aslaner Ak ,&nbsp;Birsen Sahip Yesiralioğlu ,&nbsp;Pelin Ertop Doğan ,&nbsp;Şehmus Ertop","doi":"10.1016/j.htct.2024.04.025","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.025","url":null,"abstract":"<div><h3>Objective</h3><p>Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal expansion of myeloid blasts in peripheral blood, bone marrow, and/or other tissues. It is the most common type of acute leukemia in adults with an age-adjusted incidence of 3.6/100,000 in the population (1). Extramedullary leukemia (EM AML), also known as myeloid sarcoma, is a rare manifestation of acute myeloid leukemia and is usually accompanied by bone marrow involvement (2). Leukemia cutis characteristically demonstrates the infiltration of the skin by neoplastic leukocytes(3). While the extramedullary collection of leukemic cells is generally regarded as myeloid sarcoma (previously chloroma/granulocytic sarcoma), leukemia cutis is a generic term to describe specific cutaneous involvement. Although any subtype of leukemia can involve the skin, the most common types seen in clinical practice are chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) with monocytic or myelomonocytic morphology(4). We present a case diagnosed with Extramedullary AML with skin involvement, but without bone marrow involvement.</p></div><div><h3>Case report</h3><p>Case: A 60-year-old female patient who presented to the dermatology outpatient clinic in March 2023 due to painful lesions on the trunk for the past 3 months. Physical examination revealed widespread palpable firm nodular lesions on the trunk and back(figüre-1).</p></div><div><h3>Methodology</h3><p>The patient underwent a punch biopsy with differential diagnoses including eosinophilic angiomatous hyperplasia, cutaneous metastasis, lupus tumidus panniculitis, T/B-cell lymphoma. CD68, Lysozyme, CD 33, CD16, CD123, TCL-1, TdT were investigated as antibodies.Immunohistochemical examination revealed widespread positivity for lysozyme, CD68, and faint diffuse CD33 in infiltrative cells. CD16, TdT, CD123, TCL-1 were negative. Histopathological diagnosis suggests compatibility with myeloid sarcoma characterized by blast cells with myelomonocytic features, demonstrating infiltration of immature atypical hemolymphoid cells in the skin and subcutaneous biopsy material. The patient was referred to our clinic due to compatibility with myeloid sarcoma and extramedullary myeloid leukemia. Initial tests during admission showed:WBC: 3.6 10^3/µL, HGB: 11.2 g/dL, PLT: 215 10^3/µL, NE: 2.3 10^3/µL, EO: 0.1 10^3/µL, BA: 0.0 10^3/µL, LDH: 297 U/L, with other biochemical values within normal range.In the bone marrow biopsy pathology of the patient revealed increased cellularity in the bone marrow elements, grade 1 increase in reticulin and reticular fibers,positive CD34 in vascular structures, blast cell ratio of 2-3%, mild increase and aggregation of megakaryocytes with CD61, decrease in myeloid series with MPO, and increase in erythroid cell islands with Glycophorin A. Flow cytometry showed 4.6% blast cells. The cytogenetic evaluation of the patient resulted in FLT3 negative, t (15, 17), (q22, ","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S253113792400107X/pdfft?md5=feb74e0209fe3cde8ada40eb12755c17&pid=1-s2.0-S253113792400107X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PETECHIAL RASH ON THE SKIN DUE TO THE USE OF POLYMYXIN B: A RARE CASE REPORT","authors":"Emel Akbudak Yerdelen ,&nbsp;Ayşe Günay ,&nbsp;Seda Yılmaz ,&nbsp;Abdulkadir Baştürk","doi":"10.1016/j.htct.2024.04.024","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.024","url":null,"abstract":"<div><h3>Objective</h3><p>Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria (1,2). The most important side effect of intravenous polymyxins is nephrotoxicity, neurotoxicity. Hypersensitivity reactions including rash, itching, urticaria, and fever have also been reported. It can also cause skin hyperpigmentation (3,4,5). We will present the rash thought to have developed due to polymyxin in an elderly patient diagnosed with AML.</p></div><div><h3>Case report</h3><p>A 77-year-old male patient diagnosed with AML was admitted to the hospital for a chemotherapy session. After the initial examination, he was hospitalized due to complaints of dyspnea, weakness, and cough. Polymyxin B was started upon recommendation to the patient, who was consulted with the department of chest diseases and infectious diseases regarding his current infection status.</p><p>Results: During the follow-up, petechial rashes and itching began to occur on both lower legs, starting from the ankle and spreading upwards, and it was noted that the rash and itching occurred after the use of polymyxin B. After the suspected drug was discontinued, the itching gradually decreased, and the rash was observed to become widespread and change color. The patient's rashes were photographed, and his follow-up continued and after comleting the treatment he was discharged.</p></div><div><h3>Conclusion</h3><p>In this multidrug-resistant Gram-negative bacteria era, the use of polymyxines has spread. Due to the use of these agents, adverse events such as pruritus, maculapapular rashes, and urticaria may occur (6). Patients should be observed for hypersensitivity reactions related to polymyxin B use, and the cause of these symptoms should be enlightened with the right anamnesis.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001068/pdfft?md5=2bd5e03ce2f9abd523285dcf369af56e&pid=1-s2.0-S2531137924001068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UNEARTH WRONG BLOOD TRANSFUSION BY PURSUING MIXED FIELD REACTION","authors":"Melek YANASIK ,&nbsp;Ulku KAFTANCIOGLU ,&nbsp;Zehra KOCYIGIT CAKIR ,&nbsp;Burcu DUMAN YILDIRIM ,&nbsp;Cigdem ATESMEN ,&nbsp;Neriman YANIK ,&nbsp;Zeynep OGUZ ,&nbsp;Tulin TUNC ,&nbsp;Sevgi KALAYOGLU-BESISIK","doi":"10.1016/j.htct.2024.04.045","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.045","url":null,"abstract":"<div><h3>Case report</h3><p>ABO-incompatible blood transfusions are potentially life-threatening. The common cause is skipping the final bedside check. Potential intensive and emergent transfusions have the risk of a blood component-patient matching hitch. A 58-year-old bleeding patient with anesthesia received the 4th RBC unit. Pretransfusion tests showed hemolysis in a mixed field. The returned empty bag confirmed the wrong blood group RBC transfusion. The blood bank and hemovigilance intervened; the incident was recorded</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001275/pdfft?md5=298e0a8751088945026521b1c4021f46&pid=1-s2.0-S2531137924001275-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"THE RARITY OF PRIMARY CUTANEOUS MALIGNANT MELANOMA OF THE BREAST REQUIRES SPECIAL CONSIDERATION IN THE MANAGEMENT.","authors":"Ebtihaj Hassan ,&nbsp;Suad Enaami ,&nbsp;Jalal Eltabib","doi":"10.1016/j.htct.2024.04.042","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.042","url":null,"abstract":"<div><h3>Objective</h3><p>Cutaneous malignant melanoma of the breast is a rare tumor, accounting for less than 5% of all malignant melanomas, Surgical resection is the commonly adopted treatment method for malignant melanoma, supplemented by chemotherapy, radiotherapy, and immunotherapy treatments, resulting in a comprehensive treatment strategy. We aim to assess the efficacy of adjuvant radiotherapy in managing cutaneous malignant melanoma of the breast in long-term local and regional control.</p></div><div><h3>Case report</h3><p>A 65-year-old Libyan woman was diagnosed with stage III primary cutaneous malignant melanoma of the breast in 2021. She presented with a progressive painless mass of preexisting nevus, which is located on the skin of the upper inner quadrant of her left breast post-wide local excision without ipsilateral regional lymph node sampling. A month later, a regional ipsilateral axillary LN recurrence occurred. Modified radical mastectomy and axillary LN dissection were done.</p></div><div><h3>Methodology</h3><p>subsequently, six cycles of chemotherapy were received, followed by 40 GY in 15 fractions of adjuvant radiotherapy to the left chest wall, ipsilateral axilla, and supraclavicular LNs. In November 2022, lung metastasis was identified, and immunotherapy was advised, Subsequent imaging up to January 2024 indicated no local or regional recurrences and a complete disappearance of lung metastasis.</p></div><div><h3>Results</h3><p>The rarity of cutaneous malignant melanomas of the breast has made it difficult to evaluate a life-threatening disease in which local recurrence and regional or distant metastasis may develop after surgical removal of MM, which is common. Wide local excision and prophylactic lymphadenectomy, including radical mastectomy, gave the best long-term local and regional control. Internal mammary node Dissections are not indicated; radiotherapy decreases locoregional failure from 30-50 % to 10–20%.</p></div><div><h3>Conclusion</h3><p>Given the notable local, regional recurrence, and distal metastasis rate, local radiotherapy and immune checkpoint inhibitors monotherapy could serve as potent adjuvant treatment in metastatic cutaneous breast malignant melanoma.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S253113792400124X/pdfft?md5=c6b0e3b63bdaca4708995dfb37b4c4d1&pid=1-s2.0-S253113792400124X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AUTOLOGOUS STEM CELL TRANSPLANTATION EXPERIENCE IN B-ALL DEVELOPING DURING MAINTENANCE LENALIDOMIDE TREATMENT:CASE REPORT","authors":"Kemal Fıdan ,&nbsp;Gülşah Akyol ,&nbsp;Ali Ünal ,&nbsp;Muzaffer Keklik ,&nbsp;Nursima Çukadar","doi":"10.1016/j.htct.2024.04.016","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.016","url":null,"abstract":"<div><h3>Case report: Introduction</h3><p>Secondary leukemias that occur after chemotherapy are mostly myelodysplastic syndrome and acute myeloid leukemias.With the recent increased use of immunomodulatory (IMID) drugs (pomalidomide, thalidomide and lenalidomide); It has been shown that secondary leukemias increase. Acute lymphoblastic leukemia (ALL) has frequently been described in association with IMID.</p><p>Here, we present our second ASCT experience in a case who underwent autologous stem cell transplantation (ASCT) with the diagnosis of multiple myeloma and developed B-ALL during the maintenance lenalidomide treatment.</p><p><strong><em>Key words:</em></strong> Multipl myelom, B-ALL, autologous stem cell transplantation</p></div><div><h3>Case report</h3><p>A 62-year-old female patient was diagnosed with multiple myeloma (MM) in 2017.The patient was given 4 cycles of BED (bortezomide, cyclophosphamide, dexamethasone) treatment.The patient, who was in remission, underwent ASCT with Melphalan 200 mg/m2 preparation regimen in 2018.After ASCT, the patient was started on lenalidomide maintenance treatment. Approximately 4 years later, in 2022, during the course of lenalidomide treatment, CALLA+ B-ALL was diagnosed with a bone marrow biopsy.The patient was given hyper-CVAD Chemotherapy. The patient, who was in remission after the treatment, underwent ASCT again in 2023, for the second time with the TBI + endoxan protocol (3.8 × 106/kg cells) with peripheral blood stem cells collected during the previous MM disease period.</p></div><div><h3>Discussion and conclusion</h3><p>ALL can develop due to cytotoxic agents and immunomodulatory (IMID) drugs such as alkylating agents and topoisomerase inhibitors. Alkylating agents such as Melphalan can cause the development of AML or MDS, often through unbalanced chromosomal abnormalities from first use. The incidence of secondary ALL developing after primary malignancy is 2.3%. Secondary malignancies are a known, albeit rare, complication of long-term lenalidomide therapy. However, the incidence of secondary ALL due to lenalidomide is very low. Parrondo et al demonstrated a significant increase in the risk of secondary malignancies following lenalidomide maintenance following high-dose melphalan and autologous hematopoietic stem cell transplantation in patients with multiple myeloma (MM). 4-17% of these malignancies are hematological malignancies. After ASCT, maintenance lenalidomide has now become the standard treatment for multiple myeloma. Lenalidomide creates a basis for the development of hematological malignancy secondary to treatment in these patients. However, considering the use of melphalan in the chemotherapy regimen before ASCT, lenalidomide alone cannot be blamed for treatment-related ALL. However, as a result of our literature review, there is a stronger association between lenalidomide maintenance therapy and treatment-associated ALL in multiple myeloma patients.</p><p>Therefore, in case of susp","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924000981/pdfft?md5=1fe6a98b7ca1cc54999591b337e5be0f&pid=1-s2.0-S2531137924000981-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Follicular Dendritic Cell Sarcoma (FDCS) patients treated with Chemoimmunotherapy","authors":"Berksoy Sahin,&nbsp;Birol Guvenc","doi":"10.1016/j.htct.2024.04.021","DOIUrl":"https://doi.org/10.1016/j.htct.2024.04.021","url":null,"abstract":"<div><p>Here we report 2 patients presenting with bulky lymphadenopathy in the abdominopelvic region.</p><p>The first patient was a 64 yr old man and a lymph node biopsy from inguinal region revealed a CD23-positive, CD20-negative, CXCL13-positive and Ki67 40% positive follicular dendritic cell sarcoma. The patient received 6 courses of chemotherapy combined with PD-1 MoAb (pembrolizumab. A gemcitabine plus docetaxel regimene (GemDoc) combined with 200 mg pembrolizumab. At the end of 6 courses, PET/CT presented a metabolic CR. We continue the same cheomoimmuno regimene as maintenance treatment.</p><p>The second patient is a 44 year old man who has an intraabdominal bulky tumor and multiple hepatic metastasis. Core biopsies from liver lesions and intra-abdominal mass revealed FDCS. The patient took the first course of the same regimene of chemoimmunotherapy composed of a GemDoc+pembrolizumab and felt comfortable because of the decrease in tumor sizes.</p><p>A very rare entity, FDCS has no a standart treatment, yet. We combine a second line sarcoma regimen (GemDoc) with Anti-PD1 Ab, pembrolizumab as induction systemic treatment and followed by a maintenance Pembrolizumab. This chemoimmunotherapy regimen suggest that it will work in FDCS patients who have intermediate PD-L1 expression in tumor cells.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924001032/pdfft?md5=af0cd244713ccd1834c8130512d8e76a&pid=1-s2.0-S2531137924001032-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}